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ABSTRACT 33 
Objective: Differentiated Thyroid Cancer (DTC) commonly occurs in women of child-34 
bearing age and represents the second most frequent tumor diagnosed during pregnancy 35 
only behind breast cancer. It is possible that associated physiological changes could 36 
favour tumor development and growth. However, few data are available about the 37 
outcome of DTC related to pregnancy, leading to conflicting results. Methods: 340 38 
patients with DTC <45 years old were retrospectively studied. Patients were divided into 39 
three groups according to the time of tumor diagnosis respect of pregnancy. Group 1: 40 
diagnosis of DTC at least 2 years after delivery, Group 2: diagnosis during pregnancy or 41 
within the second year after delivery, Group 3: nulliparous patients at the time of diagnosis. 42 
We evaluated clinical outcome and immunohistochemical expression of estrogen receptor 43 
α (ERα), estrogen receptor β (ERβ), progesterone receptor (PGR) and aromatase. We 44 
also analysed the gene expression of NIS and the prevalence of BRAF V600E mutations. 45 
Results: Persistence/recurrence of disease was significantly higher in group 2 patients 46 
than control groups (p: 0.023). No significant differences were observed in other clinical 47 
parameters. Furthermore no difference among the groups were recorded about ER 48 
pattern, NIS expression and BRAF mutations. Conclusions: Persistence/recurrence of 49 
DTC is significantly higher in pregnant patients, suggesting that pregnancy could really 50 
exert a negative prognostic role in patients with DTC. The underlying mechanisms are not 51 
yet clarified and further studies are required. Our results suggest that a more careful follow 52 
up is needed when diagnosis of DTC occurs during pregnancy or shortly after. 53 
 54 
Abbreviations 55 
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DTC: differentiated thyroid cancer; rhTSH: Recombinant human thyroid stimulating 56 
hormone; Tg: tireoglobuline; S-Tg: tireoglobuline measured under suppressive therapy 57 
with l-T4; A-Tg: tireoglobuline measured at ablation with I-131; rhTSH-Tg: tireoglobuline 58 
measured after stimulation with rhTSH; AbTg: Anti-Tireoglobuline Antibody; MTS: 59 
metastasis; ER: estrogen receptor; AR: androgen receptor; PGR: progesterone receptor; 60 
RAI; radioiodine ablations with I-131; NIS: Na-I symporter 61 
 62 
INTRODUCTION 63 
Differentiated Thyroid Cancer (DTC) is a relatively rare neoplasia. It represents 3.6% of all 64 
malignant tumors in the United States (SEER Cancer Statistics Review, National Cancer 65 
Institute Surveillance, Epidemiology, and End Results; 1975–2005. Available from 66 
http://seer.cancer.gov) and it is generally characterized by good prognosis. Consequently, 67 
studies evaluating the prognosis of this tumor have to consider a wide number of cases 68 
and a long-term follow-up to highlight differences in survival or disease recurrence rate. 69 
The majority of relapses usually occurs within 5 years from the initial treatment, and only 70 
sporadic cases have been subsequently documented (1, 2). Despite the low incidence, in 71 
the USA DTC represents the second most frequent diagnosed tumor during pregnancy, 72 
only after breast cancer. In women of child-bearing age about 10% of thyroid carcinomas 73 
is diagnosed during pregnancy or early after delivery (SEER Cancer Statistics Review, 74 
National Cancer Institute Surveillance, Epidemiology, and End Results; 1975–2005. 75 
Available from http://seer.cancer.gov). These findings have led to hypothesize that during 76 
this period the presence of several physiologic changes, such as hormonal secretion, 77 
growth factors and negative iodine balance, could create a favourable environment for the 78 
development and growth of tumors. 79 
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However, only few studies about the outcome of DTC related to pregnancy have been 80 
published. A recent review (3) reports that pregnancy is not generally described in 81 
literature as a determining condition for prognosis of DTC, neither in terms of DTC-related 82 
death (4), nor of overall survival (5, 6) .  83 
Nevertheless, these findings are in contrast with the more recent study published by 84 
Vannucchi et al. (7), who reported that DTC in pregnant women had a significant increase 85 
of persistent/recurrent disease than those in non pregnant patients. Since the parameters 86 
and the methodology in each study were very different, their results were not easily 87 
comparable. In fact, the studies conducted by Yasmeen et al. (5) and Herzon et al. (6), 88 
focused mainly on the overall survival, while the study of Moosa and Mazzaferri (4) had 89 
DTC-related death and disease recurrence, evaluated by biopsy or by 131-I uptake in 90 
distant sites, as primary focus. On the contrary, Vannucchi et al. (7) have evaluated 91 
persistent/recurrent DTC through more sensitive tests, such as basal and stimulated Tg 92 
levels after exogenous TSH injection (rhTSH, Thyrogen®, Genzyme Corporation, Sanofi 93 
Company, Cambridge, MA) which have not been used in the other studies and may - at 94 
least partially - explain the different conclusions. 95 
Moreover, Vannucchi et al. (7) observed a significantly higher immunohistochemical 96 
expression of the Estrogen Receptor α (ERα) in tumors from pregnant women compared 97 
to the control groups. With special reference to hormone receptor expression in thyroid 98 
tumors, a recent study (8) on the immunoistochemical expression of estrogen and 99 
androgen receptors (AR) in DTC showed that ERα was acquired or increased in tumor 100 
samples as compared to the corresponding normal tissue, whereas AR and ERß 101 
expression was decreased in tumors compared with the surrounding normal tissue. These 102 
patterns appeared also to be associated with the clinical behaviour, being the high 103 
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expression of ERα and AR and the low expression of Erß associated with a more 104 
aggressive phenotype.  105 
In such a controversial situation, we therefore designed the present study to characterize 106 
at clinical, phenotypical and molecular levels DTC cases in pregnancy as compared to 107 
matched control groups. 108 
 109 
MATHERIAL AND METHODS 110 
Patients 111 
We retrospectively evaluated more than 1200 medical records of patients with DTC treated 112 
and followed up from 2001 to 2011 at the Nuclear Medicine Department of Mauriziano 113 
Hospital, which covers up to 80% of all radioiodine ablations with I-131 (RAI) performed in 114 
the Piedmont region. This allowed us to obtain an extremely homogeneous population, 115 
representative of DTC epidemiology in the fertile women population. 116 
Among them, 340 women were selected according to the following inclusion criteria:  117 
 Age ≤ 45 years at the time of surgery 118 
 Total thyroidectomy 119 
 I-131 radioiodine ablation  120 
 L-T4 TSH-suppressive therapy (TSH ≤0.1 mU/l) (9) 121 
 Follow up ≥ 1 year 122 
 rhTSH test during follow up or persistent disease (S-Tg > 2 ng/ml) 123 
 124 
Patients were divided into three groups according to the time of diagnosis of DTC respect 125 
to pregnancy. Group 1 included women (n=152, median age 40, range 25-45) with DTC 126 
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diagnosis at least 2 years after delivery. Group 2 included women (n=38, median age 35, 127 
range 26-41) with diagnosis of DTC during pregnancy or within two years after delivery. 128 
Group 3 included nulliparous patients at the time of diagnosis (n=150, median age 30, 129 
range 15-45).  130 
Tumors were classified following the World Health Organization classification (10), staged 131 
according to the 6th edition of TNM staging (American Joint Committee on Cancer, AJCC). 132 
(11) and classified as Low and High Risk according to the European Consensus 133 
Statement criteria (9). ETA guidelines divide patients into three groups: Very Low, Low and 134 
High Risk but the first group was not represented in our series because it includes patients 135 
with no indications for RAI . 136 
Remission or persistent/recurrent disease were defined according to the European and 137 
American guidelines for the management of DTC (9, 12): 138 
 REMISSION: S-Tg and rh-TSH-Tg < 0,6 mcg/l, negative AbTg and  139 
     normal neck ultrasound. 140 
 PERSISTENT/RECURRENT disease at least one of the following criteria:  141 
- S-Tg > 2 μg/L 142 
- rh-TSH-Tg > 2 μg/L 143 
- Persistence of AbTg > 4 years with a trend to increase (an increasing 144 
antibody production or newly antibodies appearance as a consequence of an 145 
increased of autoantigen production) (13, 14) 146 
- Neck or distant MTS 147 
- Radioiodine uptake outside thyroid bed 148 
 149 
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Serum Tg levels were measured during L-T4 withdrawal, immediately before RAI and after 150 
12 months of L-T4 suppressive therapy. Then, patients received one injection of rh-TSH 151 
(0.9 mg i.m., Thyrogen®, Genzyme Corporation, Sanofi Company, Cambridge, MA) for two 152 
consecutive days; serum samples for TSH and Tg measurements were collected on days 153 
0 (before first rh-TSH administration), 3 and 4. Neck ultrasonography was performed 6 and 154 
12 months after RAI. TSH levels were evaluated using a chemiluminescent immunoassay 155 
(Access Immunoassay Systems, Beckman Coulter®, Inc.), Tg levels were determined 156 
using chemiluminescent immunoassay (Access Immunoassay Systems, Beckman 157 
Coulter®), with a functional sensitivity of 0.6 µg/L; Ab-Tg antibodies were detected with 158 
chemiluminescent immunoassay (Access Immunoassay Systems, Beckman Coulter®, 159 
Inc.). Based on Tg assay, we considered 0.6 μg/L as the cut-off value between 160 
undetectable and measurable Tg levels, according to Mazzaferri et al. (1) 161 
 162 
Immunohistochemical analysis of hormone receptors and aromatase in tumor 163 
tissues 164 
Immunohistochemical evaluation of estrogen receptor α (ERα), estrogen receptor ß (ERß), 165 
progesterone receptor (PGR) and aromatase were performed in 37 histological specimens 166 
selected from the three different groups (12 of group 1, 10 of group 2, 15 of group 3). 167 
Cases for immunohistochemical analysis were blinded selected to obtain 3 groups  168 
homogenous in terms of age and stage, regardless of the outcome.  169 
Immunohistochemical analyses were carried out on paraffin-embedded tissue sections of 170 
5 μm, after dewaxing, dehydration in alcohol and rehydration in PBS pH 7,5. Endogenous 171 
peroxidase block was performed by immersion of the slides in 0,3% solution of methanol 172 
and hydrogen peroxide for 15 minutes. Then sections were incubated with the following 173 
monoclonal primary antibodies: ERα (clone 1D5, dilution 1:300, Dako, Glostrup, DK), ERβ 174 
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(clone PPG5/10, dilution 1:50, Dako), PGR (clone 636, dilution 1:300, Dako), and 175 
Aromatase (clone mca2077s, dilution 1:50, Serotec, Kidlington, UK). A biotin-free, dextran 176 
chain-based detection system (EnVysion, Dako) and diaminobenzidine as the chromogen 177 
were used according to standard protocols. All markers were assessed in tumoral and 178 
peritumoral tissue using H-score evaluation, which takes into account both quantitative 179 
and qualitative expression with a 0-300 range scale. 180 
 181 
Molecular analysis 182 
Nucleic acids isolation. Genomic DNA was isolated from formalin-fixed, paraffin-183 
embedded tissues using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). RNA was 184 
isolated from paraffin embedded material using the high pure RNA paraffin kit (Roche, 185 
Mannheim, Germany) following the manufacturer’s instructions. The quantity of isolated 186 
DNA and RNA was assessed using a Biophotometer (Eppendorf, Hamburg, Germany). 187 
BRAF point mutation analysis. The presence of BRAF point mutation (V600E) was 188 
analysed using pyrosequencing and PCR primers following previously published protocols  189 
(15). PCR amplification for the pyrosequencing assay was performed according to 190 
standard protocols. The amplicons were mixed with sequencing primers and sequencing 191 
was performed using a PyroGold reagent kit (Biotage AB) according to the manufacturer’s 192 
protocol. Results were analyzed using the PSQ-96 MA 2.0.2 software (Biotage). 193 
Quantitative real time PCR  for the sodium/iodide symporter. 194 
Relative cDNA quantitation of the sodium/iodide symporter (NIS) and an internal reference 195 
gene (-actin) were done using a fluorescence-based real-time detection method [ABI 196 
PRISM 7900 Sequence Detection System (Taqman); Applied Biosystems/Life 197 
technologies, Foster City, CA]. Beta-actin primers and probe were previously published  198 
(16), whereas for NIS the TaqMan gene expression assay 20X (SLC5A5 199 
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Hs00166567_m1, Applied Biosystems) was used according to manufacturer’s intructions. 200 
The PCR reaction mixture consisted 1,200 nmol/L of each primer, 200 nmol/L probe, 200 201 
nmol/L each of dATP, dCTP, dGTP, dTTP, 3.5 mmol/L MgCl2, and 1x Taqman Universal 202 
PCR Master mix to a final volume of 20 µL (all reagents were from PE Applied 203 
Biosystems,). Cycling conditions were 50°C for 2 minutes, 95°C for 10 minutes, followed 204 
by 46 cycles at 95°C for 15 seconds and 60°C for 1 minute. To analyze target gene 205 
expression in individual tumors, the relative gene expression levels were expressed as 206 
ratios (differences between the Ct values) between 2 absolute measurements (genes of 207 
interest/internal reference gene). Then, the ΔΔCt values were calculated subtracting ΔCt 208 
values of each case to the value of the normal sample expression, and converting the ratio 209 
by the 2−ΔΔCt formula; cases were considered of low or high expression according to the 210 
median expression level obtained.  211 
 212 
Statistical analysis 213 
The clinical (age, outcome, number of treatments, ablation-Tg levels, High/Low risk 214 
classification) and pathological/molecular features (histology, pTNM stage, hormone 215 
receptor expression, NIS gene expression and BRAF mutation status) were compared 216 
among the three groups of patients by using the χ2 test for dichotomic variables and the 217 
Mann Whitney and Kruskal-Wallis tests for continuous variables, as appropriate. The 218 
reciprocal correlation among immunohistochemical markers was evaluated using the 219 
Spearman’s test. Statistical significance was defined as p<0,05. 220 
A logistic multivariable analysis was performed. Dependent dichotomous variable was 221 
tumor persistence/recurrence (1) or remission (0). Age, T, N and multifocality of primary 222 
tumor and pregnancy (DTC diagnosis during pregnancy or within 2 years after delivery: 1; 223 
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Other groups: 0) were the independent variables. All these analyses were performed using 224 
STATISTICA for Windows Ver. 8.0. 225 
 226 
 227 
RESULTS 228 
Clinical, biochemical, histopathological and molecular parameters in the three groups are 229 
reported in Table 1.  230 
No significant differences were noticed in the number of treatments for achieving clinical 
remission, in the tumor size or extrathyroidal invasion, in the lymphnodal metastatic 
involvement at diagnosis, in histology and in High Risk/Low Risk classification of patients 
according to the ETA guidelines (9).  
Clinical remission was obtained in 150/152 patients (98.7%) of group 1, 34/38 patients 231 
(89.5%) of group 2 and in 143/150 patients (95.3%) of group 3. Persistent/recurrent 232 
disease was observed in 2/152 patients (1.3%) of group 1, 4/38 patients (10.5%) of group 233 
2 and in 7/150 patients (4.7%) of group 3. Our results showed a significant difference (χ2 : 234 
7.532, P= 0.023) in the outcome among the three groups, with a greater percentage of 235 
persistent disease in group 2 than in group 1 and 3. Group 1 and 3 did not show any 236 
significant difference. Only 4/38 patients in group 2 had cytological diagnosis while 237 
pregnant. They underwent thyroidectomy in the early postpartum period, achieving clinical 238 
remission, showing that the surgical delay of few months was not a factor that could 239 
influence the worst outcome of group 2.  240 
As regards the expression of hormone receptors (Figure 1), the percentage of intratumoral 241 
and peritumoral expression of ERα in the 37 histological samples were globally low, with 242 
no detection of significant differences between the groups (P=0.96). ERβ showed a high 243 
expression in the peritumoral tissue in a large number of cases, while in tumoral tissue its 244 
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expression was quite variable, similarly in the three groups (P=0.82). PGR expression was 245 
mostly negative in peritumoral tissue, while it was quite variable in tumoral tissue, in a 246 
similar way in the three groups (P=0.41). A significant correlation was observed in tumor 247 
tissue between ERα and PGR (Spearman’s R value: R=0.49; P=0.002). Aromatase was 248 
negative both on peritumoral and tumoral tissue in all the samples analyzed. BRAF V600E 249 
mutation, known as a negative prognostic factor (18), was detected in 25% in group 1, 250 
44,4% in group 2 and  60% in group 3 (average of whole samples= 43%). The difference 251 
was not statistically significant (P=0.191) showing that the worst outcome observed in 252 
patients of group 2 is independent from BRAF mutation. However, BRAF was mutated in 253 
100% of patients with persistence of disease and in 37,5% of patients in remission, 254 
irrespective of the group.  255 
NIS gene expression levels were also not different in the three groups (P=0.82) nor 256 
associated to BRAF mutation status (P=0.55).  257 
Logistic multivariable analysis performed on the whole population (thus excluding 258 
molecular analyses) showed pregnancy (Group 2) as the unique independent variable for 259 
persistent/recurrent DTC prediction. The relative risk (RR) was 1.12 (95% CI 1.02-1.22; 260 
p=0.02). Age, T, N and multifocality of the primary tumor did not enter the model.  261 
In the 37 patients with molecular and immunohistochemical data available, BRAF mutation 262 
and low NIS expression were strong independent predictors of persistence/recurrence of 263 
DTC (Table 2), whereas ERα and PGR did not enter the model. Pregnancy and ERβ 264 
positivity were of borderline statistical significance.  . 265 
Power analysis was performed grouping the entire population into patients with DTC 266 
during or within 2 years after delivery (38 subjects) vs all other patients (302 subjects), with 267 
values of 79% and 87%,. by two-sided and one-sided tests, respectively. 268 
 269 
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DISCUSSION 270 
Thyroid cancer discovered during pregnancy represents a challenge for the clinicians 271 
because, at present, there are still no reliable data available supporting a specific 272 
management of pregnancy-associated DTCs. Currently pregnant patients with a 273 
citologically suspicious thyroid nodule for DTC do not require surgery during pregnancy 274 
except in cases of rapid nodular growth and/or the appearance of lymph node metastases 275 
(19). 276 
Most studies showed that pregnancy did not worsen the prognosis of DTC. In four studies, 277 
the prognosis of women with DTC diagnosed either during pregnancy or within the first 278 
postpartum period was compared to that of women diagnosed at another time as controls. 279 
In three of these works (4-6), no difference was found in DTC prognosis between pregnant 280 
women and control groups. However, in the fourth study (7), Vannucchi et al. reported a 281 
significant worse outcome in pregnant patients. As a matter of fact, they observed 60% of 282 
recurrent/persistent disease in pregnant women (group 2) vs 4.2% in women with DTC 283 
diagnosed more than 1 year after delivery (group 1) and 13.1% in nulliparous patients 284 
(group 3). Moreover, a higher expression of ERα in tumor samples of pregnant women 285 
was reported.  286 
In order to verify these conflicting results, we selected a homogeneous population, dividing 287 
patients into three groups according to the criteria adopted by Vannucchi et al.. We 288 
extended group 2 to women with DTC diagnosis within 2 years after delivery instead of 1 289 
year, arbitrarily assuming that in tumors with low biological aggressiveness, such as DTC, 290 
pregnancy-induced hyperestrogenism may exert its tissue activity in a longer period. At our 291 
knowledge no published data are available on this issue. Moreover, in our population the 292 
rate of persistent/recurrent disease in patients diagnosed within 1 year or between 1 and 2 293 
years after delivery was very similar (9,5% - 2/21 cases - and 11,7% - 2/17 cases – 294 
respectively). On the contrary, all the patients (14/14) diagnosed between 2 and 3 years 295 
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after delivery displayed clinical remission. 296 
Consistent with the data reported by Vannucchi et al, we confirmed a significant correlation 297 
between pregnancy and a worse outcome of DTC (p= 0,023), representing the unique 298 
independent variable for persistent/recurrent disease prediction. 299 
Indeed, thyroid cancer diagnosed during pregnancy (group 2) was found to be significantly 300 
associated with persistence or relapse of DTC compared to those diagnosed more than 2 301 
years after delivery (group 1) or before pregnancy (group 3).  302 
Taken together, recent evidence supports the hypothesis that pregnancy may negatively 303 
affects the prognosis of DTC. The discrepancy with previous studies could be attributed to 304 
the different criteria used for the outcome evaluation, as suggested elsewhere (3). 305 
Previous papers used the overall survival, DTC-related death and disease recurrence 306 
(evaluated by biopsy or whole body scan) as outcome criteria, which were probably not 307 
appropriate for a long survival disease with frequent indolent course. In the present study, 308 
according to Vannucchi et al., the persistence/recurrence of disease was investigated 309 
using more sensitive and precocious markers such as basal and rhTSH stimulated 310 
thyroglobulin and neck ultrasonography, as suggested by European and American 311 
guidelines (9, 12).  312 
Nevertheless, the worst outcome in patients of group 2 cannot be referred to a higher 313 
prevalence of a worse staging at the time of diagnosis or to a more aggressive histological 314 
phenotype because, in our study, no significant differences in the examined clinical and 315 
morphological parameters were observed. 316 
The mechanisms by which pregnancy could affect the DTC outcome are not easily 317 
explainable. In order to verify whether molecular and/or phenotypical features were 318 
influencing the results above, we tested the protein expression of sex hormone receptors, 319 
as well as the gene expression of NIS and the prevalence of BRAF mutations in the three 320 
groups. Indeed, we cannot support the negative prognostic role of estrogens, as previously 321 
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suggested (7), considering that our results did not show any significant expression of ERα 322 
and no differences among the three groups were observed. The discrepancy between 323 
these results has to be clarified, but a difference in the methodological approach could be 324 
considered. For example different antibody dilutions were used in the two works (1:300 vs 325 
1:100 dilution). However, it has to be noted that the good correlation between the low 326 
expression of ERα and PGR justifies the reliability of our findings. The 327 
immunohistochemical analysis was performed also for the detection of ERβ, showing a 328 
variable expression without any significant difference among the three groups of patients. 329 
Furthermore, aromatase expression resulted generally very low, leading us to keep out its 330 
potential pathophysiological role. 331 
In the multivariable logistic regression analysis, BRAFV600E mutations are associated with a 332 
worse prognosis, but their similar distribution among the groups excludes a 333 
pathophysiological role on the poorer outcome of group 2 patients .  334 
We hypothesized that the worse outcome of group 2 could be explained by a lower 335 
response to radioiodine therapy. As resulted by the multivariable logistic regression 336 
analysis, NIS lower expression is associated with a higher persistence/recurrence of DTC, 337 
but its distribution was not different among the three groups, excluding a role in affecting 338 
the outcome of group 2. 339 
In conclusion, our results, obtained in a large homogeneous population, confirm that 340 
pregnancy could really exert a negative prognostic role, at least in terms of risk of 341 
persistent disease or recurrence, in patients with differentiated thyroid cancer. Further 342 
studies are needed to clarify the pathophysiological mechanisms. At the present state of 343 
our knowledge, a more careful follow up is needed when diagnosis of DTC occurs during 344 
pregnancy or shortly after. However, the impact on DTC prognosis is not so heavy to justify 345 
the reconsideration of the American guidelines for the management of thyroid cancer 346 
during pregnancy (19). 347 
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FIGURE LEGENDS 439 
Figure 1. Immunohistochemical analysis of hormone receptors. A case of multifocal 440 
papillary carcinoma (group 3)  (a; H&E, original magnification 40x), with the predominant 441 
nodule of the follicular variant (b; H&E, original magnification 200x), and high expression 442 
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of  ERα (c), ERβ (d) and PGR (e) (c-d-e: immunoperoxidase, original magnification 200x); 443 
f: scatter plot graphs of the distribution of hormone receptors in the three groups of DTC.  444 
 445 
TABLES 446 
Table 1. Clinical, histological and molecular characteristics of patients with a DTC 447 
diagnosis at least 2 years after delivery (Group 1), during pregnancy or within two years 448 
after delivery (Group 2), or  before pregnancy/nulliparous (Group 3) 449 
* Group 2 was significantly different as compared to both group 1 and group 3. 450 
** The ablation-HTG cut-off was defined according to Webb et al. (17) 451 
 452 
 453 
Table 2: Logistic regression analysis for persistence/recurrence of DTC 454 
 455 
 456 
Table 1 457 
 458 
 Group 1 Group 2 Group 3 P value 
Age at diagnosis (years): 
Median (range) 
40 (25-45) 35 (26-41) 30 (15-45) <0.001 
Duration of follow up (years): 
Median (range) 
5 (1-27) 6 (1-10) 6 (1-20) 0.31 
Remission 150/152 (98.7%) 34/38 (89.5%) 143/150(95.3%) 
0,023* 
Persistence/recurrence 2/152 (1.3%) 4/38 (10.5%) 7/15 (4.7%) 
Number of treatments 1,19 1,21 1,28 0,22 
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(average) 
Ablation-HTG <10 ng/ml  ** 127/152 (83,5%) 27/38 (71%) 110/150 (73,3%)   
0,060 
Ablation-HTG >10 ng/ml ** 25/152 (16,5%) 11/38 (29%) 40/150  (26,7) 
High Risk 68/152 (44.7%) 19/38 (50%) 79/150  (52,7%) 
0,38 
Low Risk 84/152 (55.3%) 19/38 (50%) 71/150  (47,3%) 
TNM (T<3) 105/152 (69%) 26/38 (68.4%) 95/150  (63.3%) 
0,85 
TNM (T>3) 47/152 (31%) 12/38 (31.6%) 55/150  (36.7%) 
TNM (N -) 114/152 (75%) 29/38 (76.3%) 102/150  (68%) 
0,54 
TNM (N +) 38/152 (25%) 9/38 (23.6%) 48/150  (32%) 
Histology (High Risk) 54/152 (35.5%) 16/38 (42.1%) 62/150  (41.3%) 
0,85 
Histology (Low Risk) 98/152 (64.5%) 22/38 (57.9%) 88/150  (58.7%) 
ERα tumor expression 3/12 (25 %) 3/10 (30 %) 4/14 (28.6 %) 0.96 
ERβ tumor expression 5/12 (41.7%) 5/10 (50%) 7/15 (46.7%) 0.92 
PGR tumor expression 4/12 (33.3%) 3/10 (30%) 8/15 (53.3%) 0.419 
BRAF V600E mutation 3/12 (25%) 4/9 (44.4%) 9/15 (60%) 0,19 
NIS fold change <1  8/12 (66,6%) 5/8 (62,5%) 9/13 (69,2%) 0,9 
 459 
 460 
 461 
Table 2 462 
 463 
Variable RR (95% CI) P value 
Pregnancy 1.26 (0.97-1.55) 0.09 
Erβ positive staining 0.69 (0.38-1.00) 0.06 
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Presence of BRAF 
mutation 
1.46 (1.16-1.77) 0.005 
High NIS expression 0.66 (0.36-0.96) 0.03 
 464 
 465 
